XORTX Therapeutics Inc. (XRTX)Healthcare | Biotechnology | Calgary, Canada | NasdaqCM
2.34 USD
-0.11
(-4.376%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.50 +0.16 (6.929%) ⇧ (Aug. 28, 2026, 4:54 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:39 a.m. EDT
The immediate outlook is severely clouded by a board chair resignation and a statistically weak short-term forecast leaning negative, suggesting near-term volatility without a clear catalyst to drive a bounce. However, the long-term picture is catastrophic: the business has suffered a structural collapse, dropping nearly 99.4% over the last three years with three consecutive years of negative annual returns. This multi-year decline indicates a fundamental deterioration where the market has priced out the asset entirely, rendering any current valuation metrics irrelevant. Furthermore, the company offers no income stream whatsoever, having paid no dividends in the last five years while burning through significant cash reserves. The combination of deteriorating governance, a collapsed price trajectory, and zero capital return capability makes this a clear avoidance candidate. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.037289 |
| MSTL | 0.063411 |
| AutoETS | 0.068988 |
| AutoARIMA | 0.096990 |
| MSTL_94 | 0.147597 |
| MSTL_94_122 | 0.148812 |
| MSTL_122 | 0.155933 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 0.52 |
| Ljung-Box p | 0.085 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 2.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 4,247,129 |
| Forward P/E | 2.92 |
| Beta | 0.08 |
| Previous Name | Hakuta Matata Finance |
| Website | https://www.xortx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.40487802 |
| Address1 | 3,710 - 33rd Street NW |
| All Time High | 2,478.6 |
| All Time Low | 1.725 |
| Ask | 2.95 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 10,630 |
| Average Daily Volume3 Month | 13,616 |
| Average Volume | 13,616 |
| Average Volume10Days | 10,630 |
| Beta | 0.076 |
| Bid | 1.67 |
| Bid Size | 2 |
| Book Value | 1.497 |
| City | Calgary |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.338 |
| Current Ratio | 3.586 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.4374 |
| Day Low | 2.3 |
| Display Name | XORTX Therapeutics |
| Earnings Timestamp | 1,786,797,000 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -2,146,440 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.516 |
| Enterprise Value | 3,253,084 |
| Eps Forward | 0.8018253 |
| Eps Trailing Twelve Months | -2.47 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.10094 |
| Fifty Day Average Change | 0.23706007 |
| Fifty Day Average Change Percent | 0.11283524 |
| Fifty Two Week Change Percent | -40.4878 |
| Fifty Two Week High | 7.05 |
| Fifty Two Week High Change | -4.712 |
| Fifty Two Week High Change Percent | -0.66836876 |
| Fifty Two Week Low | 1.725 |
| Fifty Two Week Low Change | 0.61300004 |
| Fifty Two Week Low Change Percent | 0.35536233 |
| Fifty Two Week Range | 1.725 - 7.05 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,632,403,800,000 |
| Float Shares | 1,791,278 |
| Forward Eps | 0.8018253 |
| Forward P E | 2.9158473 |
| Free Cashflow | -2,581,080 |
| Full Exchange Name | NasdaqCM |
| Fullday Change | -0.107 |
| Fullday Change Percent | -4.37627 |
| Fullday Price | 2.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07835 |
| Held Percent Institutions | 0.04186 |
| Implied Shares Outstanding | 1,816,565 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-13 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,775,433,600 |
| Last Split Factor | 1:5 |
| Long Business Summary | XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada. |
| Long Name | XORTX Therapeutics Inc. |
| Market | us_market |
| Market Cap | 4,247,129 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_259860883 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -3,739,137 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,992,778 |
| Open | 2.35 |
| Operating Cashflow | -5,100,467 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 403 455 7727 |
| Post Market Change | 0.16199994 |
| Post Market Change Percent | 6.928996 |
| Post Market Price | 2.5 |
| Post Market Time | 1,787,950,484 |
| Prev Name | Hakuta Matata Finance |
| Previous Close | 2.445 |
| Price Hint | 4 |
| Price To Book | 1.5617903 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.592 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.106999874 |
| Regular Market Change Percent | -4.376273 |
| Regular Market Day High | 2.4374 |
| Regular Market Day Low | 2.3 |
| Regular Market Day Range | 2.3 - 2.4374 |
| Regular Market Open | 2.35 |
| Regular Market Previous Close | 2.445 |
| Regular Market Price | 2.338 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 22,035 |
| Return On Assets | -0.29851 |
| Return On Equity | -0.99244004 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,816,565 |
| Shares Percent Shares Out | 0.0104 |
| Shares Short | 18,856 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 23,621 |
| Short Name | XORTX Therapeutics Inc. |
| Short Percent Of Float | 0.0106 |
| Short Ratio | 1.38 |
| Source Interval | 15 |
| State | AB |
| Symbol | XRTX |
| Total Cash | 994,045 |
| Total Cash Per Share | 0.547 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.411885 |
| Two Hundred Day Average Change | -0.073884964 |
| Two Hundred Day Average Change Percent | -0.030633701 |
| Type Disp | Equity |
| Volume | 22,035 |
| Website | https://www.xortx.com |
| Zip | T2L 2M1 |